---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-24-000055"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:22:48.282583+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q3 2024 revenue up 5.9% to $191.2M; adjusted EPS down to $0.96

## Summary
- Net revenues $191.2M vs $180.6M in Q3 2023, up 5.9%.
- GAAP net income $40.4M ($0.78 diluted EPS) vs $49.2M ($0.91) year ago.
- Adjusted non-GAAP net income $49.6M ($0.96 diluted EPS) vs $61.9M ($1.15).
- Growth driven by BAQSIMI and Primatene MIST; Primatene on track for $100M annual sales.
- No updated guidance provided in the release.

## SEC filing metadata
- accession: 0001297184-24-000055
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718424000055/0001297184-24-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718424000055/amph-20241106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-24-000055
- JSON: https://secwatch.observer/filing/0001297184-24-000055.json
- Plain text: https://secwatch.observer/filing/0001297184-24-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.